Recipharm reaches agreement with LobSor Pharmaceuticals

Manufacturing of a proprietary treatment for advanced Parkinson’s disease

09-Sep-2015 - Sweden

Recipharm and LobSor Pharmaceuticals announced the formation of a manufacturing agreement for LECIGON™.  As part of the agreement, Recipharm will have exclusive manufacturing rights for volumes representing first three years of commercial sales.  Recipharm will also support development costs against a mark-up on manufacturing prices, up to a certain volume, when LECIGON is produced for commercial sales.  

This agreement is a follow-on to an established collaboration between LobSor and Recipharm for the development and the manufacturing of batches for the recently completed clinical trial.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance